Published in J Urol on March 17, 2008
Tumour location as a predictor of benign disease in the management of renal masses. Can Urol Assoc J (2010) 1.49
The impact of tumour size on the probability of synchronous metastasis and survival in renal cell carcinoma patients: a population-based study. BMC Urol (2014) 1.44
DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer (2011) 1.40
Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol (2014) 1.39
Metastatic renal cell carcinoma risk according to tumor size. J Urol (2009) 1.35
Solid renal masses: what the numbers tell us. AJR Am J Roentgenol (2014) 0.90
The Prognostic Factors for Patients with pT1a Renal Cell Carcinoma. Korean J Urol (2010) 0.87
Correcting the Shrinkage Effects of Formalin Fixation and Tissue Processing for Renal Tumors: toward Standardization of Pathological Reporting of Tumor Size. J Cancer (2015) 0.86
Assessment and characterisation of common renal masses with CT and MRI. Insights Imaging (2011) 0.86
Significance of chromosome 9p status in renal cell carcinoma: a systematic review and quality of the reported studies. Biomed Res Int (2014) 0.86
Small renal masses: surgery or surveillance. Korean J Urol (2013) 0.85
Characteristics of aggressive variants in T1a renal cell carcinoma. J Cancer Res Clin Oncol (2011) 0.83
The role of pathology in small renal mass laparoscopic cryoablation. Adv Urol (2012) 0.81
Management of small renal masses: a review. World J Urol (2010) 0.80
Risk of metastasis for T1a renal cell carcinoma. World J Urol (2015) 0.78
Stage T1N0M0 renal cell carcinoma: the prognosis in Asian patients. Chin J Cancer (2011) 0.78
Gender differences in benign renal masses. World J Urol (2013) 0.78
Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma. Oncol Lett (2014) 0.78
Percutaneous radiofrequency ablation of renal tumors: a single-center experience. Korean J Urol (2013) 0.77
Words of wisdom. Re: Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. Eur Urol (2009) 0.75
Clinical Outcome of Small Renal Cell Carcinoma after Delayed Surgery versus Immediate Surgery. J Cancer (2013) 0.75
The role of GAGE cancer/testis antigen in metastasis: the jury is still out. BMC Cancer (2016) 0.75
Accuracy capabilities comparisons between Karakiewicz, Kattan and Cindolo nomograms in predicting outcomes for renal cancer carcinoma: A systematic review and meta-analysis. Can Urol Assoc J (2015) 0.75
FOXC2 and CLIP4 : a potential biomarker for synchronous metastasis of ≤7-cm clear cell renal cell carcinomas. Oncotarget (2016) 0.75
Radiofrequency ablation: a minimally invasive approach in kidney tumor management. Cancers (Basel) (2010) 0.75
The behavior of renal cell carcinoma: sex, lies and tumor size. J Urol (2008) 0.75
A Huge Renal Cell Carcinoma, Nine Years after Its Primary Diagnosis and Obligate Observation. Case Rep Oncol (2010) 0.75
Natural history and management of small renal masses. Curr Oncol (2009) 0.75
Small (<4 cm), Unclassified Renal Cell Carcinoma Presenting with Initial Bone Metastasis: A Case of a Metastatic Lesion Missed at the Initial Diagnosis. Korean J Urol (2012) 0.75
Metastatic renal cell carcinoma mimicking diverticulitis in a patient with chronic lymphocytic leukaemia. BMJ Case Rep (2015) 0.75
Surveillance for the management of small renal masses. Adv Urol (2008) 0.75
Severe blood loss anaemia and recurrent intussusceptions as first presentation of bowel metastatic renal cell carcinoma: A case report and review of the literature. Mol Clin Oncol (2017) 0.75
EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol (2010) 8.21
Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol (2008) 3.83
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am (2003) 3.44
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Renal cell carcinoma guideline. Eur Urol (2007) 3.42
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res (2003) 3.30
Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol (2007) 3.26
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res (2003) 3.25
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol (2005) 3.15
Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol (2004) 3.06
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06
Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol (2007) 2.92
Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol (2002) 2.91
Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol (2008) 2.80
Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen. J Urol (2009) 2.77
Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res (2005) 2.67
Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol (2009) 2.55
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45
The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol (2011) 2.43
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41
Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol (2010) 2.38
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer (2007) 2.38
Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol (2008) 2.37
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int (2008) 2.35
Percutaneous ultrasound-guided renal biopsy in supine antero-lateral position: a new approach for obese and non-obese patients. Nephrol Dial Transplant (2007) 2.31
Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol (2007) 2.30
The conserved transcriptome in human and rodent male gametogenesis. Proc Natl Acad Sci U S A (2007) 2.30
Laboratory and clinical development of single keyhole umbilical nephrectomy. Urology (2007) 2.28
Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. Eur Urol (2013) 2.26
Using preoperative albumin levels as a surrogate marker for outcomes after radical cystectomy for bladder cancer. Urology (2013) 2.25
Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology (2009) 2.17
Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol (2006) 2.15
Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer (2005) 2.15
TachoSil(®) sealed tubeless percutaneous nephrolithotomy to reduce urine leakage and bleeding: outcome of a randomized controlled study. J Urol (2012) 2.14
Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy. Urology (2012) 2.13
Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol (2011) 2.10
Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol (2006) 2.09
Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol (2007) 2.09
Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate (2004) 2.09
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol (2005) 2.05
Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol (2005) 2.05
SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer. Cancer Res (2009) 2.03
Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist (2009) 1.99
Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol (2007) 1.96
Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol (2009) 1.92
Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol (2009) 1.90
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol (2007) 1.90
Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Mod Pathol (2005) 1.89
Prognostic value of thrombocytosis in renal cell carcinoma. J Urol (2006) 1.87
Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol (2011) 1.87
Secondary hormonal therapy for advanced prostate cancer. J Urol (2006) 1.86
Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol (2009) 1.83
Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol (2010) 1.82
p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol (2007) 1.81
Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol (2012) 1.81
The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? Eur Urol (2009) 1.78
A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol (2008) 1.77
Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? J Urol (2009) 1.75
Metabolism of kidney cancer: from the lab to clinical practice. Eur Urol (2012) 1.75
Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol (2009) 1.73
Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate (2009) 1.73
Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol (2004) 1.70
Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU Int (2007) 1.69
Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature. Eur Urol (2013) 1.69
N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia (2009) 1.68
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol (2007) 1.67
Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol (2004) 1.65